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Abstract (English) 
While antiretroviral therapy decreases HIV/AIDS morbidity and mortality, long-term 
treatment results in insulin resistance and cardiovascular diseases. A possible cause of 
such adverse effects may be an increase in oxidative stress resulting from protease 
inhibitor (PI)-induced mitochondrial dysfunction. We therefore hypothesized that PI 
treatment, specifically Lopinavir/Ritonavir, results in increases in myocardial reactive 
oxygen species (ROS), leading to downstream outcomes, i.e. elevated apoptosis. 
Moreover, we proposed that increased ROS levels in this instance might occur as a result 
of PI-mediated induction of the non-oxidative glucose pathways (NOGPs).  In light of 
this, we also investigated the effect of PI treatment on the NOGPs by employing both in 
vitro and in vivo samples. For the in vitro work we employed a rat cardiomyoblast cell 
line, while tissues (heart, liver) were collected from two separate experimental models, i.e. 
a) Group A exposed to PIs via mini-osmotic pump for a period of eight weeks, and b) 
Group B administered PIs via a jelly-based method for 16 weeks.  
We found that PIs increased mitochondrial ROS levels in vitro but that this was not 
accompanied by a parallel rise in programmed cell death. Moreover, we found no 
induction of the NOGPs in response to PI exposure (for both in vitro and in vivo models 
here employed). However, we found that the AGE pathway was significantly down-
regulated in the liver of Group A. Investigation into a proposed mechanism for this 
observation proved inconclusive and further studies are thus required to clarify the 
significance in terms of metabolic dysfunction found in the Group A model. Our study 
thus shows that PIs can increase ROS levels (in vitro) but that compensatory antioxidant 
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mechanisms may prevent this in vivo.  Subsequently, downstream effects were limited i.e. 
we did not observe NOGP induction and programmed cell death.  An intriguing finding 
emerged, however, i.e. that PIs can elicit an impact on the AGE pathway. We propose 
future studies with modifications to the current rat and cell models in order to evaluate 
the downstream effects of PIs on the NOGPs and programmed cell death. 
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Abstract (Afrikaans) 
Terwyl antiretrovirale terapie MIV/VIGS morbiditeit en mortaliteit verlaag, veroorsaak 
langtermyn behandeling insulienweerstandigheid en kardiovaskulêre siekte.  ‟n 
Moonltike oorsaak van sulke newe-effekte kan ‟n toename in oksidatiewe stres 
veroorsaak deur die protease inhibeerder (PI)-geïnduseerde mitochondriale 
wanfunskionering.  Ons hipotetiseer dat PI behandeling, spesifiek Lopinavir/Ritonavir, 
versoorsaak „n toename in miokardiale reaktiewe suurstofspesies (ROS), wat aanleiding 
gee tot afstroom uitkomste, i.e. verhoogde apoptose. Verder, stel ons voor dat verhoogde 
ROS vlakke in hierdie geval onstaan as gevolg van PI-gemedieerde induksie van die nie-
oksidatiewe glukose weë (NOGWe).  In die lig hiervan het ons ook die effek van PI 
behandeling op die NOGWe ondersoek deur beide in vitro en in vivo monsters te gebruik.  
Vir die in vitro werk het ons van „n rot kardio-mioblastsellyn gebruik gemaak, terwyl 
weefsels (hart, lewer) versamel is van twee afsonderlike eksperimentele modelle, i.e. a) 
Groep A blootgestel aan PIs via mini-osmotiese pomp vir ‟n periode van agt weke, en b) 
Groep B PIs is toegedien via ‟n jellie gebaseerde metode vir 16 weke.  
Ons het bevind dat die die PIs mitochondriale ROS vlakke in vitro verhoog maar dat dit 
nie vergesel is met „n paralelle toename in apoptose. Verder is geen induksie van die 
NOGWe in reaksie op PI blootstelling waargeneem (vir beide in vitro en in vivo modelle). 
Hoewel ons het bevind dat die AGE weg in die lewer van Groep A beduidend 
afgereguleer is. Ondersoek na „n moontlike megansime vir hierdie waarneming was 
onoortuigend en verdere ondersoek is nodig om die betekenis in terme van die 
metaboliese wanfunskionering in die Groep A model vas te stel.  Ons studie toon dus aan 
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dat PIs, ROS vlakke (in vitro) verhoog, maar dat kompensatoriese anti-oksidant 
meganismes in die hierdie in vivo model verhoed word.  Gevolglik is die afstroom effekte 
beperk i.e. ons het geen NOGWe induksie en aptoptose waargeneem nie.  ‟n Interesante 
bevinding het wel uitgestaan, i.e. PIs kan „n impak hê op die AGE weg. Ons stel dus voor 
dat toekomstige studies met modifikasies, tot die huidige rot- en sel-modelle gemaak 
word om die afstroomeffekte van PIs en apoptose te evalueer.   
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Introduction 
The incidence of human immunodeficiency virus (HIV) infection has shown a dramatic 
increase over the past two decades. According to recent data released by UNAIDS the 
number of persons living with HIV in South Africa amounts to almost 6 million
1
. While 
this number is alarmingly high, it does not vary much from the data collected by the 
World Health Organization in 2007
2
. This indicates that the prevalence of the HIV/AIDS 
epidemic in South Africa is beginning to decrease, potentially attributed to improved 
access to highly active anti-retroviral therapy (HAART).  
 
Although HAART increases the life expectancy of affected individuals, its long-
term usage leads to various cardio-metabolic derangements, including cardiovascular 
diseases (CVD). Protease inhibitors (PIs) are an integral class of HAART with a variety 
of side-effects including the development of hyperlipidemia, hyperinsulinemia, 
hypertriglyceridemia and hypercholesterolemia
3–5
. PIs cause inflammation resulting in 
myocardial stress, which potentially predicts the onset of insulin resistance (IR) and 
cardiovascular abnormalities including myocardial infarction (MI) and CVD. 
Furthermore, PI-treated HIV-infected individuals show evidence of increased reactive 
oxygen species (ROS) production, which may activate harmful signaling and cell death 
pathways. 
 
Unfortunately the underlying mechanisms for HAART-induced cardio-metabolic 
derangements are not well understood. Therefore our focus is to identify key metabolic 
pathways that mediate PI-induced cardio-metabolic pathophysiology. We hypothesize 
Stellenbosch University  http://scholar.sun.ac.za
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that PIs induce the activation of the non-oxidative glucose pathways (NOGPs), resulting 
in a concurrent increase in ROS and subsequent cell death. This review will briefly focus 
on HIV infection and its potential contribution towards adverse cardio-metabolic 
perturbations, whereafter the emphasis will shift to the effects elicited by HAART.  Here 
we will focus on especially the role of HIV-PIs and the potential role of particular 
metabolic circuits such as the NOGPs. 
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The role of HIV infection in cardiovascular diseases 
The defining characteristic of HIV infection is that of a compromised immune system, 
ultimately leading to chronic, life-long inflammation and development of acquired 
immunodeficiency syndrome (AIDS). Prior to the development of HAART, various 
cardiac abnormalities were observed in HIV-infected patients, including dilated 
cardiomyopathy, endo-, myo- and peri-carditis, and pulmonary hypertension
6–9
. The 
direct effects of HIV on cardiac tissue is linked to the stages of HIV/AIDS infection
10
. 
Such effects will of course compound the negative prognosis and survival of HIV-
infected individuals. Thus it is important to distinguish between the effects of 
antiretrovirals (ARVs) (focus of this thesis) and HIV infection per se in terms of the 
development of CVD and related abnormalities. 
Various studies highlighted the challenge of chronic immune activation to the 
myocardium and the role of HIV in the development of CVD. For example, Becker et 
al.
11
 found that HAART naïve HIV-infected patients with acute coronary syndrome 
(ACS) displayed less traditional risk factors for CVD than their HIV-negative 
counterparts with ACS. However, the thrombotic burden was significantly higher and 
angiographic characteristics altered. These findings were confirmed in similar studies
12,13
 
and all data indicated the pathogenesis of CVD in HIV-infected individuals. HIV-infected 
individuals with ACS were compared to both HIV-negative and diabetic non-ACS 
individuals. Although all three groups displayed similar levels of multi-vessel disease, 
HIV-infected patients were significantly younger and had less complex lesions than their 
controls. Furthermore, the degree of subclinical coronary atherosclerosis was increased in 
the HIV-infected cohort
13
. Therefore it is evident that HIV itself is involved in viral-
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mediated pathway activation that leads to the development of thrombotic and 
atherosclerotic disease infection, as well as the customary risk factor pathways.  
With the advent of HAART, we are faced with the conundrum of co-morbidity, as 
now not only is HIV infection associated with an increased risk for future health 
complications, but long-term HAART usage can elicit side-effects such as increased 
cardiovascular complications
14
 (Figure 1). For example, HIV infection is associated with 
renal, vascular and pulmonary complications, more commonly associated with the 
geriatric population. Moreover, while HAART offers significant benefits in terms of the 
overall well-being of HIV-infected individuals, there are some concerns regarding side-
effects.  
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Figure 1. The detrimental side-effects of HIV infection per se and HAART
15
. Numerous organ systems 
can be negatively affected by HIV infection. While HAART dramatically decreases the HIV burden, it can 
also trigger a number of side-effects in some HIV-infected individuals. IR – insulin resistance, T2DM – 
type 2 diabetes mellitus. 
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The development of HAART 
 
The advent of ARV usage sparked a noted increase in the life expectancy and quality of 
life of HIV-infected individuals, and has become essential tool to combat the devastating 
effects of HIV. The mechanism of action of ARVs is the inhibition of the viral life cycle 
at stages essential for proliferation of the virus (Figure 2). There are three distinct classes 
of ARVs which will be briefly discussed i.e. reverse transcriptase (RT) inhibitors 
(including non-nucleoside reverse transcriptase inhibitors [NNRTIs] and nucleoside 
reverse transcriptase inhibitors [NRTIs]), integrase inhibitors, and PIs.  
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Figure 2. HIV lifecycle and targets for ARVs
15
. 1. The virus docks and infiltrates the host cell. 2. Single-
strand viral RNA enters the host nucleus. 3. HIV RT and nucleosides transcribes single-stranded RNA. 4. 
Double-stranded RNA is produced which 5. Enters the nucleus and integrates itself within the host‟s DNA 
via HIV integrase. 6. Transcription allows viral mRNA production for viral proteins, 7. Gag and Gag-pol 
multi-protein complexes are formed and bud at the host‟s cell wall where proteases cleave proteins and 
mature viral particles. HAART can inhibit key viral enzymes at various stages of the viral life cycle. RT – 
reverse transcriptase, NRTI, NNRTI - nucleoside and non-nucleoside reverse transcriptase inhibitors, PI - 
protease inhibitors, DNA – deoxyribonucleic acid, HIV – human immunodeficiency virus, mRNA – 
messenger RNA, RNA – ribonucleic acid. 
Reverse transcriptase inhibitors 
RT inhibitors inhibit HIV-1 RT, an essential viral enzyme. Here this enzyme is 
responsible for the conversion of the positive single stranded RNA viral genome into 
double stranded DNA, which then becomes integrated into the host cell chromosomes
16
. 
RT is an appealing target for drug development as it is essential for HIV replication yet 
not required for host cell metabolism and thus has the potential to limit HIV-1 infection.  
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RT inhibitors can be divided into two classes: NRTIs and NNRTIs. NRTIs 
function by causing termination of DNA elongation via integration into newly 
synthesized DNA during reverse transcription. Elongation is disrupted due to chain 
terminators lack of the functional 3‟-OH group required for the addition of nucleotides16. 
NNRTIs function by binding in a hydrophobic pocket next to the catalytic site of RT in 
HIV-1 and thereby inhibit viral replication
17
. While such inhibitors are effective in 
controlling viral proliferation in HIV-infected individuals, usage is often accompanied by 
a variety of adverse effects. 
For example, medium- to long-term NRTI usage can cause inhibition of 
mitochondrial DNA polymerase γ, resulting in impairment of the synthesis of 
mitochondrial enzymes that generate ATP via oxidative phosphorylation
18
. A summary 
of the mitochondrial toxicities caused is shown in Table 1, with the severity of symptoms 
increasing with the duration of therapy. Adverse effects may also be exacerbated by 
underlying organ dysfunction, e.g. chronic liver disease, simultaneous HIV-1 
opportunistic diseases, or via drug co-administration with similar toxicity profiles. 
NNRTIs display less severe side-effects and can elicit a positive effect on high density 
lipoproteins (HDL). For example, treatment with efavirenz causes elevated HDL levels, 
lowering the low density lipoprotein (LDL)/HDL cholesterol ratio and thus resulting in 
an improved lipid profile
19
. 
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Table 1: Adverse effects associated with different classes of ARVs
33
 
Class Drug Side effects 
NRTIs Zidovudine 
 
Stavudine didanosine 
 
 
 
Abacavir 
 
Tenovir 
Anemia, nausea, rash, 
myopathy, dyslipidemia 
Nausea, lipoatrophy, DSPN, 
dyslipidemia, pancreatitis, 
lactic acidosis, hepatic 
streatosis, heart disease 
HSR, hepatotoxicity, heart 
disease 
Renal insufficiency, bone loss 
NNRTIs Efavirenz 
 
 
Nevripine 
Etravirine 
CNS adverse effects, rash, 
hepatotoxicity, lipoatrophy, 
teratogenicity 
Rash, HSR, hepatotoxicity 
Rash, hepatotoxicity 
PIs All PIs 
 
 
Atazanavir 
 
Indinavir 
 
Lopinavir fosamprenavir 
Nausea, diarrhea, rash, 
dyslipidemia, IR, 
hepatotoxicity 
Jaundice, scleral icterus, 
nephrolithiasis 
Jaundice, scleral icterus, 
nephrolithiasis 
Heart disease 
Integrase inhibitors Raltegravir Headache, insomnia, 
dizziness, fatigue 
DSPN - distal sensory peripheral neuropathy, HSR - hypersensitivity reactions, CNS – central nervous 
system, IR – insulin resistance 
Stellenbosch University  http://scholar.sun.ac.za
 25 
Integrase inhibitors 
HIV integrase is responsible for the integration of the viral cDNA into the genome of 
infected cells and also acts as a cofactor for reverse transcription, and is therefore 
essential for viral replication
20
. While integrase is necessary for viral proliferation, there 
is no host-cell equivalent and hence integrase inhibitors will not alter normal cellular 
processes.  However, at relatively high doses (10-20 times higher than recommended) 
some integrase inhibitors can have an effect on recombinases required for normal 
antibody production
21
 as well as inhibiting RNase H
22
. This has been attributed to the 
structural similarities between integrases, recombinases and RNases
23
.  
 Integrase inhibitors show the least adverse effects when compared to other drug 
classes (Table 1); however it is a relatively new ARV and limited long-term studies have 
yet been performed. However, naïve HIV-infected individuals treated for 24 weeks with 
raltegravir (in combination with tenofovir and lamivudine) displayed no significant 
changes for fasting serum cholesterol, LDL-cholesterol, HDL-cholesterol or triglyceride 
levels
24
. To assess the effects of integrase inhibitors on their own the BENCHMRK 
(Blocking integrase in treatment Experienced patients with a Novel compound against 
HIV: MeRcK) trials were established. Results following a 96-week treatment period 
indicate similar side effects as previously reported
25
. 
Due to the low side-effect profile currently observed, patient adherence to the 
drug regimen might be higher than with other ARVs. This will then allow for future 
studies revealing long-term adverse effects as well as genetic influences with regard to 
drug resistance. 
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Protease inhibitors 
More than 10 HIV PI-type drugs have been developed since the initiation of HAART in 
1995
26
. PIs function by acting as an inhibitor of HIV aspartyl protease, resulting in the 
production of immature, non-infectious viral particles
27
, with no effect on cells already 
containing integrated viral DNA. PIs form an integral part of combination therapy, 
suppressing viral load and increasing CD4
+
 count, leading to decreased morbidity and 
mortality among HIV-infected individuals
28
.  
 The development of combination ARVs represented an important step in the fight 
against HIV/AIDS. Often combination therapy consists of NNRTIs or PIs in conjunction 
with NRTIs, subsequently referred to as HAART. One such example of effective 
combination therapy is Lopinavir/Ritonavir, the latest PI developed, which forms part of 
second-line HAART in South Africa, and the focus of this study.  
Kumar et al.
29
 examined the metabolism of Lopinavir in various species and ascertained 
the maximal binding of this compound following uptake and release into circulation was 
to plasma proteins. They further discovered that Lopinavir was taken up by most tissues, 
albeit to varying degrees, including the rat heart. 
Both Lopinavir and Ritonavir are heterocyclic compounds, with the liver the major site 
for Lopinavir metabolism i.e. by hepatic enzymes cytochrome P450 3A4 (CYP3A4) and 
cytochrome P450 3A5 (CYP3A5)
30
, resulting in a number of oxidative metabolites 
although the main compound remains the major circulating drug. However, the 
circulating concentration of Lopinavir is insufficient to effectively suppress viral 
replication. Since Ritonavir is able to inhibit CYP3A4 and CYP3A5 thereby increasing 
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the plasma concentration of Lopinavir
31,32
, a co-formulation drug was developed, i.e. 
Lopinavir/Ritonavir, also known as Kaletra™ or Aluvia™ 31.  
PIs elicit an extensive side-effect profile (Table 1). It can cause gastrointestinal problems 
and metabolic abnormalities such as IR, hypertriglyceridemia and hypercholesterolemia. 
Since the focus of this study is on the cardio-metabolic effects of PIs, these topics will be 
covered more extensively in the next section. 
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Cardiovascular complications as a result of PI usage 
 
 PIs are associated with increased risk for myocardial infarction (MI) and coronary 
syndromes. For example, a large clinical study investigating the risk for MI with HAART, 
i.e. the Data Collection for Adverse events of Anti-HIV Drugs (DAD) Study group, 
recruited 23 468 HIV-infected patients on HAART
34–36
. Here accumulative exposure to 
HAART was linked to a significant increase in MI incidence, especially with PIs. In total 
1.5 % of patients experienced MI. After adjusting for confounding parameters, the 
outright risk for MI was low although HAART and PIs increased normal CVD risk 
factors such as cholesterol and lipid abnormalities, and T2DM. Results from other studies 
followed a similar trend where the absolute risk of MI remains low
37,38
 but where PIs are 
associated with a significant increase in the occurrence of MI
34,35,37–39
. Furthermore, 
increasing duration of HAART exposure, including PIs, can increase mortality and 
hospitalization for cardiovascular complications in the long term. 
The use of Ritonavir, while boosting the efficacy of Lopinavir, also presents its own set 
of complications. For example, Ritonavir usage is associated with echocardiographic 
abnormalities, including significant rates of left ventricular systolic and diastolic 
dysfunction, as well as pulmonary hypertension and enlargement of the left atria
40
. Thus 
while effective in their role as HIV suppressors, PIs specifically are associated with the 
onset of cardiovascular complications. However, the association between PI usage and 
atherosclerosis is also disputed, with some studies disregarding the link
41,42
 while others 
reveal a clear relation with the development of subclinical atherosclerotic lesions
43–46
 and 
thrombotic environments
47,48
. Moreover, PIs are also strongly associated with the 
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development of increased risk for MI and coronary syndromes. Together this shows that 
HIV PIs are linked to the onset of cardiovascular complications and to various metabolic 
disorders, thereby triggering damaging effects at multiple levels. 
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The effect of PIs on metabolism 
 
Metabolic perturbations can develop from PI usage, for example the metabolic syndrome 
(MetS), a culmination of risk factors predisposing the patient to the future onset of type 2 
diabetes mellitus (T2DM) and CVD
49
. While criteria for defining the MetS vary, the 
chief risk factors include abdominal obesity, atherogenic dyslipidemia, IR, raised blood 
pressure, pro-inflammatory status and pro-thrombotic state
49–51
. Focusing on PI treatment, 
various studies based on cell-
52–55
, animal-
56–58
 and human-based
59–65
 models 
demonstrated increased plasma cholesterol and triglyceride levels, lipodystrophy and IR 
as the most common metabolic perturbations.  Collectively these metabolic derangements 
can lead to the development of inflammation, which in turn can stress the myocardium 
and may eventually progress to cardiac dysfunction and also to the onset of IR
63,66
.  Thus 
this becomes a vicious metabolic cycle. 
A variety of alterations to glucose metabolism were also found with PI usage, 
including the impairment of glucose tolerance. This includes whole-body glucose 
disposal, glucose uptake, transport and phosphorylation, as well as the development of IR 
at peripheral sites, e.g. skeletal muscle
59,67,68
. Several studies found that IR is associated 
with PI usage even in the absence of apparent hyperglycemia
68
. For example, Walli et 
al.
69
 reported that the insulin sensitivity of HIV-infected individuals receiving PIs was 
significantly lower than control patients and HAART-naïve patients. Furthermore, a 
decrease in insulin sensitivity was also noted in HIV-negative patients receiving PI 
treatment. These results were confirmed in a similar study performed by Behrens et al.
58
. 
While PI usage can elicit direct effects on the development of IR, the HIV virus itself 
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may also be implicated
68
. Thus the picture that emerges is more complex and likely 
includes the effects of both PIs and the virus. 
We therefore propose that, at the molecular level, PIs activate essential metabolic 
pathways to initiate a range of unfavorable alterations, which ultimately leads to the 
development of the above-mentioned metabolic derangements. Furthermore, these lipid- 
and glucose-mediated alterations may contribute to related pathophysiologies, i.e. an 
increase in oxidative stress, mitochondrial abnormalities, IR/T2DM and CVD. 
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PI usage and the development of oxidative stress 
 
PI usage is correlated to increased reactive oxygen species (ROS) production and has 
been investigated by a number of studies utilizing human-
70
, animal-
71–74
, and cell-
based
75–79
 models. Here a variety of tissue and cell types were investigated (Table 2) and 
the general consensus is that PI usage is linked to an increase in the production of oxidant 
species, as well as the activation of pro-oxidant pathways, which eventually leads to an 
increase in oxidative stress within such cells and tissues.  
Table 2. Various cell and tissue types investigated for PI-induced increases in ROS 
Author Cell/Tissue type Outcomes 
Wang, X. et al.
78
 
Lagathu, C. et al.
80
 
Macrophages Mitochondrial dysfunction, 
cholesterol efflux, ROS 
Deng, W. et al.
81
 Cardiomyocytes ROS, Cl- currents 
Chai, H. et al.
82
 
Jiang, B. et al.
83
 
Endothelial cells endothelial mitochondrial 
dysfunction, mtROS 
Mondal, D. et al. 
84
 Intestinal epithelial cells mononuclear cell 
recruitment, ROS 
Wang, X. et. al
77
 Pulmonary aortic endothelial 
cells 
eNOS synthase 
expression, superoxide 
anion levels 
Chandra, S. et. al 
74
 Pancreatic β-cells ROS, cytosolic SOD 
Touzet, O. & Phillips, A.
75
 
Zaera, M. et al.
71
 
Human skeletal muscle cells ROS, mitochondrial 
respiratory chain 
dysfunction, mtDNA 
deletions 
Wang, X. et al.
77
 
 
Pocine arteries eNOS expression, 
superoxide anion levels 
eNOS – endothelial nitric oxide synthase, mtROS – mitochondrial ROS, SOD – superoxide dismutase, 
mtDNA – mitochondrial DNA. 
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However, intracellular ROS levels depend on both pro-oxidant systems and ROS-
removal machinery. These systems cooperate to ensure optimal intracellular ROS levels 
at any given time. 
ROS are formed intracellularly by cellular components, including the 
mitochondrial electron transport chain (ETC)
85,86
, nicotinamide adenine dinucleotide 
phosphate oxidases (NOX)
87,88
, xanthine oxidase
89,90
, and cytochrome P450
91,92
. However, 
while there are many ROS sources, its main producer is the mitochondrion, specifically 
via the ETC - either by respiratory chain complex I or complex III located within the 
inner mitochondrial membrane
93
. ROS production begins by electrons being accepted 
from reducing equivalent molecules such as nicotinamide adenine 
dinucleotide/nicotinamide adenine dinucleotide phosphate (NADH/NADPH) and are 
passed into the ETC via mitochondrial respiratory complex I or III. Thereafter electrons 
are able to move through the ETC to the final electron acceptor in order to form water 
(H2O) in complex IV. However, a few electrons can escape the system before 
encountering the final acceptor and can catalyze the monoelectronic reduction of 
molecular oxygen (O2), to form superoxide (O2
−). Two pools of O2
− are created: firstly, 
O2
− generated by complex I in the inner mitochondrial membrane is released into the 
matrix where it is converted to hydrogen peroxide (H2O2) by manganese superoxide 
dismutase (MnSOD)
87,93
, i.e. 2 O2
− + 2H+  O2 + H2O2. Secondly, O2
−
 generated by 
complex III gets either shuttled into the mitochondrial matrix where it undergoes a 
similar fate as O2
− produced by complex I, or it is transferred to the inner mitochondrial 
membrane. Because the outer mitochondrial membrane is permeable to O2
−, it is able to 
translocate into the cytosol where copper/zinc superoxide dismutase (Cu/Zn SOD) 
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converts O2
− to H2O2 (Figure 3), which can be removed by glutathione peroxidase (GPx) 
94,95
. 
Figure 3. The production of superoxide (O2
−) by mitochondrial complex I and III
15
. Free electrons 
leaked from the electron transport chain during oxidative respiration, allow for the formation of O2
− from 
molecular oxygen in complex I and III. O2
− generated from complex I gets converted to H2O2 by MnSOD 
in the mitochondrial matrix. O2
− generated by complex III undergoes a similar fate, but also gets 
translocated to the cytosol where it converted to H2O2 by Cu/Zn SOD. SOD – superoxide dismutase. 
ROS is essential as a regulator of intracellular signaling pathways and gene expression 
under normal conditions referred to as “redox signaling”96,97. NOX regulate the 
generation of O2
− generated by the transfer of an electron from NADH/NADPH to 
molecular oxygen
98–101
. Generally the antioxidant defense system is sufficient to 
counteract the harmful effects of excessive ROS levels. However, when there is increased 
activation of ROS generating systems and/or when the antioxidant defense system is 
compromised then excess damaging ROS is produced. Here O2
− can react with nitric 
oxide to form peroxynitrite (ONOO
−
), whereas H2O2 can be converted to a hydroxyl 
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anion (OH) by non-enzymatic pathways, e.g. the Fenton reaction
102
. However, increases 
in ROS can also be due to adverse effects caused by PIs. 
The origins, mechanisms and exact sequence of events for the production of PI-
induced ROS are not well understood. While most studies suggest a mitochondrial 
origin
103
, treatment of porcine carotid arteries with Ritonavir resulted in an increased 
endothelial nitric oxide synthase (eNOS)-generated production of O2
−79. This is 
indicative of an extra-mitochondrial ROS source. PI therapy is also responsible for 
alterations in functional mitochondrial biology e.g. increasing membrane potential 
depolarization in HL-1 myocytes
82
 and lowers cellular oxygen consumption
104
.  
For this study, we propose that there is a link between increased PI-mediated ROS 
generation and downstream activation of NOGPs. A rise in blood glucose levels leads to 
an increase in flux through the glycolytic pathway resulting in more glucose being 
oxidized by the tricarboxylic acid (TCA) cycle. Subsequently, more electrons pass 
through the ETC, increasing the proton gradient across the mitochondrial membrane
105
. 
Complex III is blocked and electrons are trapped at co-enzyme Q from where it gets 
passed to O2, leading to an overproduction of O2
−106,107. Excess O2
− leads to DNA strand 
breakage and poly (adenosine diphosphate ribose) polymerase (PARP) is subsequently 
activated to repair such breaks
108
. However, PARP also inhibits a key glycolytic enzyme 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), thus confining it to the nucleus
105
. 
Consequently, glycolytic intermediates upstream of GAPDH are diverted into the 
NOGPs
109
 (Figure 4). 
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Figure 4. Inhibition of GAPDH in the nucleus leads to activation of NOGPs, four potentially 
damaging alternate pathways to glucose metabolism. PARP - poly (adenosine diphosphate ribose) 
polymerase, GAPDH - glyceraldehyde-3-phosphate dehydrogenase, SO – superoxide, OGT - O-GlcNAc 
transferase. 
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The non-oxidative pathways of glucose metabolism 
 
There are four main pathways branching off from glycolysis which are implicated in 
microvascular and macrovascular complications arising from PI-induced hyperglycemia 
and ROS production, i.e. the polyol pathway, the formation of advanced glycation end-
products (AGEs), activation of protein kinase C (PKC) and the hexosamine biosynthetic 
pathway (HBP). For this study, we propose that PI induced upregulation of NOGPs could 
occur and lead to subsequent complications (Figure 5). 
Figure 5. The four non-oxidative pathways have damaging effects. For this study, we propose that PI-
induced upregulation of the NOGPs results in oxidative stress and cardio-metabolic abnormalities. 
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The polyol pathway 
Increased flux through the polyol pathway is mediated by two enzymes i.e. aldose 
reductase (AR) and sorbitol dehydrogenase. Here AR together with its co-factor NADPH 
catalyzes the conversion of glucose to sorbitol, while sorbitol dehydrogenase (and its co-
factor NAD+) allows for the conversion of sorbitol to fructose
110
 (Figure 6). 
 
 Figure 6. The polyol pathway is regulated by two enzymes. Aldose reductase and sorbitol 
dehydrogenase catalyze the conversion of glucose to fructose. 
Three potential mechanisms for the contribution of the polyol pathway to oxidative stress 
exist. Firstly, increased AR activity may lead to the depletion of its co-factor NADPH, 
which also required by glutathione (GSH) reductase to regenerate GSH. A decrease in 
GSH, an essential antioxidant in cells responsible for the eradication of various ROS 
species, may thus lead to increased ROS levels
111
. The second mechanism involves the 
conversion of sorbitol to fructose, resulting in increased oxidative stress, as the co-factor 
for sorbitol dehydrogenase, NAD+, is converted to NADH. NADH is utilized as a 
substrate for NOX for ROS production
112
. Lastly, increased polyol flux elevates the 
amount of fructose available that may be further metabolized to fructose-3-phosphate 
(F3P) and 3-deoxyglucosone, powerful nonenzymatic glycation agents, leading to 
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increases in AGEs. Therefore we hypothesize that PI-induced increases in flux through 
the polyol pathway can lead to increased ROS levels, resulting in a number of damaging 
effects. 
Various pathologies associated with increased blood glucose are implicated with 
the formation of sorbitol. For example, Oates et al.
113
 performed animal model studies 
demonstrating that the utilization of AR inhibitors (ARI) prevented the development of 
diabetic complications. Furthermore, when diabetic rats were treated with ARIs, the GSH 
levels in the lens of the eye were higher than in untreated diabetic rats. Therefore AR 
activity causes oxidative stress
114
. However, sorbitol levels in neurons were not related to 
the severity of neural dysfunction
115
. This suggests that there may be other mechanisms 
involved in the development of diabetic lesions. For example, sorbitol accumulation-
linked osmotic stress results in a loss of GSH, which may contribute to increased 
ROS
116,117
.  
Advanced glycation end-products 
Proteins and lipids may become nonenzymatically glycated and oxidized subsequent to 
contact with aldose sugars, resulting in AGEs that are formed as a result of the Maillard 
reaction (Figure 7). Because glycation is concentration-dependent in the early stages of 
the Maillard reaction, it is heightened in diabetes
118
. The reaction begins with an initial 
glycation and oxidation event, resulting in the formation of Schiff bases and Amadori 
products, a 1-amino 1-deoxyketose, produced by the reaction of the carbonyl group of 
glucose with proteins, lipids and nucleic acids amino groups
119,120
. Thereafter, Amadori 
reorganization occurs where carbonyl groups such as α-dicarbonyls or oxoaldehydes and 
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products that include 3-deoxyglucosone and methylglyoxal (MG) can accumulate
121,122
. 
This is known as “carbonyl stress” (Figure 7).  
 
Figure 7. The Maillard reaction
123
. Reducing sugars react with the amino group of proteins to produce a 
Schiff base. Molecular rearrangements result in more stable Amadori products. Further rearrangements, 
condensations and dehydrations result in the formation of intermediate α-oxoaldehydes such as 
methylglyoxal and 3-deoxygluosone. Whether protein adducts or protein crosslinks are formed is 
dependent on the nature of early glycation events. 
3-deoxyglucosone may also be formed from F3P, derived from the polyol pathway as 
discussed previously. Moreover, MG may also be formed via non-oxidative mechanisms 
in anaerobic glycolysis
124
, and from the oxidative breakdown of polyunsaturated fatty 
acids
125
. MG may also develop from fructose by fragmentation of triose phosphate or via 
the catabolism of ketone bodies and threonine
126
. While such products may originate by 
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non-oxidative means, it can induce oxidative stress and cell death. For example, human 
monocytic leukemia cells showed increased apoptosis and oxidative stress when treated 
with varying concentrations of 3-deoxyglucosone and MG
127
. A similar phenomenon was 
observed in rat Schwann cells
128
, corticol neurons
129
, and rat mesangial cells
130
. The 
proposed mechanism for AGE-related apoptosis is via MG-mediated reduction of 
intracellular GSH and oxidative stress-mediated activation of the p38 mitogen-activated 
protein kinase (MAPK), an important kinase in cell death signaling
131
. Here the damaging 
effect of AGEs is evident and the variety of cell types affected is indicative of the scope 
of AGEs throughout the body.  
There are three possible mechanisms for AGE-related damage: Firstly, the accumulation 
of AGEs in the extracellular matrix results in cross-link formation. This causes blood 
vessels to become narrower and stiffen, resulting in atherosclerosis which is further 
exacerbated by AGE interference with matrix-cell interactions and the modification of 
LDL cholestrerol
132
. Secondly, AGE-mediated glycation of intracellular proteins may 
have an effect on signaling pathways. For example, intracellular AGEs reduce eNOS 
activity causing defective vasodilation and subsequent atherosclerosis
133
. MG is a 
precursor of intracellular AGEs that modifies antioxidant systems resulting in increased 
oxidative stress. Lastly, the interaction of AGEs with their receptors (RAGEs) results in a 
downstream signaling cascade, leading to increases in ROS via activation of the NOX 
system
134
. 
While AGEs are implicated in numerous pathologies, including diabetic microvascular 
diseases, connective tissue diseases such as rheumatoid arthritis, neurological conditions 
such as Alzheimer‟s disease, and end-stage renal disease135–137, it is not fully understood 
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whether it is the cause or effect of such conditions. For example, Raj et al.
138
 performed 
an in vitro study that implicated AGEs as part of complex interactions with oxidative 
stress and vascular damage, e.g. the development of atherosclerosis. AGEs contribute to 
oxidative stress
139,140
 by inducing free-radical production and reducing nitric oxide 
concentrations
141
, resulting in vascular thickening with loss of elasticity, hypertension 
and endothelial dysfunction, as the vasodilatory and anti-proliferative effects of nitric 
oxide on vascular smooth muscle are eliminated
142
. In this case AGEs would be the cause 
of cardiovascular derangements. With Alzheimer‟s disease, however, there are increases 
in cerebral but not plasma AGEs, suggesting that AGE accumulation with Alzheimer‟s 
disease is a highly selective, brain specific event
143
. Thus the conundrum remains 
whether AGEs are responsible for Alzheimer‟s disease or present as an effect of the 
disease.  
The formation of AGEs is almost irreversible
144
, although there is evidence that enzymes 
such as glyoxalase-1 are able to detoxify AGE precursors and inhibit AGE 
production
119,145
. Both intracellular and extracellular proteins can be glycated and 
oxidized if certain factors are taken into consideration, i.e. the turnover rate of proteins 
for glycoxidation, the degree of hyperglycemia, and the extent of environmental oxidant 
stress
119,144,146–148
. 
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The activation of protein kinase C 
PKC forms part of a family of enzymes consisting of at least eleven different isoforms. 
They are responsible for the transduction of signaling pathway cascades that stimulate the 
hydrolysis of lipids
149
, the control of basic cell autonomous activities such as 
proliferation, and memory
150
. PKC can be activated by diacylglycerol (DAG). DAG 
production is stimulated by activation of a large number of receptor families, including G 
protein-coupled receptors, tyrosine kinase receptors, and non-receptor tyrosine kinases. 
The process can be rapid e.g. by activation of specific phospholipase Cs, or more gradual 
by activation of phospholipase D. The latter results in the formation of phosphatidic acid 
and DAG production
151–153
. Some PKCs can also be activated by calcium as they contain 
a calcium-binding site similar to calmodulin. PKCs activated by calcium interact with 
membrane acidic phospholipids, e.g. phosphatidylinositol. Calcium becomes available 
again after phospholipase C cleavage of phosphatidylinositol 4,5-bisphosphate into DAG 
and inositol 1,4,5-trisphosphate (IP3). Thus multiple receptor pathways result in PKC 
activation by production of second messengers such as DAG and calcium (Figure 8). 
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Figure 8. Schematic representation of PKC activation
154
. 1. Ligand binding activates cell surface 
receptor which, 2. Activates PLC. 3. PLC cleaves PIP2 into DAG and IP3. 4. PKC is activated either by 
DAG or Ca
2+
 and undergoes a conformational change. 5. Activated PKC phosphorylates other cytosolic 
proteins. PLC – phospholipase C, PIP2 - Phosphatidylinositol 4,5-bisphosphate, IP3 - inositol 1,4,5-
trisphosphate. 
The mechanism of action of PKC is to phosphorylate serine or threonine residues in basic 
sequences
155
. Unlike protein kinase A, it does so without the need for positive charge at 
specific positions and also with a lack of stereospecificity
156
. PKC also possesses ATPase 
and phosphatase activities and is responsible for ATP hydrolysis by catalyzing a cofactor-
dependent, substrate-stimulated reaction
157
. 
PKC is implicated in numerous processes throughout the body, including receptor 
desensitization, the mediation of immune responses, the regulation of membrane structure 
events, transcription and cell growth, as well as in learning and memory
151–153,158,159
. 
Stellenbosch University  http://scholar.sun.ac.za
 45 
Because PKC is involved in the regulation of various vascular functions, it is plausible 
that the persistent PKC activation may result in numerous functional vascular anomalies 
in the diabetic patient. Moreover, with T2DM there is chronic activation of the DAG-
PKC pathway in a variety of micro- and macro-vascular tissues
160–165
. Subsequently, 
tissue DAG levels rise indicating that increased  PKC activation with diabetes occurs as a 
result of a corresponding elevation  in DAG levels.  
A proposed mechanism for the glucose-activated increased DAG levels is 
attributed to greater de novo DAG synthesis. This can be simultaneously linked to 
diabetic vascular wall dysfunction, and is further substantiated by various studies 
utilizing PKC inhibitors
165–170
. Elevated DAG de novo synthesis occurs due to increased 
formation of glucose metabolism precursors, e.g. dihydroxyacetone phosphate and 
glycerol-3-phosphate following stepwise acylation to lysophosphatidic acid and 
phosphatidic acid. The rate at which de novo DAG synthesis occurs is directly related to 
the amount of glucose available. Thus with hyperglycemia, de novo synthesis is enhanced 
because stimulation of phospholipid breakdown does not give preferentiality to glucose 
carbon incorporation into DAG
171
. Moreover, increases in saturated non-esterified fatty 
acids may also initiate the de novo synthesis of DAG and PKC activity and thereby 
increase ROS production.  
ROS production by NOX may be responsible for various vascular abnormalities. For 
example, Inoguchi et al.
172
 found that an increase in glucose as well as treatment with 
PMA (a PKC activator) led to a significant increase in ROS in cultured aortic endothelial 
cells. Furthermore, when cells were subjected to diphenylene iodonium (a NOX 
inhibitor) and calphostin C (a PKC inhibitor), respectively, ROS levels decreased. These 
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data therefore suggest that elevated glucose levels resulted in increased ROS production 
via PKC-dependent activation of NOX.  
The hexosamine biosynthetic pathway 
Increased HBP flux (by way of excess glucose or free fatty acids) results in the formation 
of amino sugars. The pathway begins with fructose-6-phosphate (F6P) being converted to 
glucosamine-6-phosphate (GlucN-6-P) via the rate-limiting enzyme glutamine:fructose-
6-phosphate-amidotransferase (GFAT), which makes use of glutamine as an amino 
donor
173,174
. GFAT is also responsible for controlling the amount of glucose that enters 
the HBP and is therefore highly regulated. Regulation takes place via: 1. The 
concentration of F6P because affinity for the GFAT substrate is low; 2. Feedback 
inhibition of GFAT activity by uridine-5-diphosphate-N-acetylglucosamine (UDP-
GlcNAc) through allosteric mechanisms
175
; 3. GFAT activity is influenced by 
intracellular GFAT protein levels
176
; and 4. GFAT activity is increased by 3΄,5΄ 
monophosphate (cAMP)-dependant phosphorylation
177
. Thus GFAT inhibition prevents 
hyperglycemia-induced abnormalities e.g. IR and other diabetic complications
174,178
.  
The further conversion of GlucN-6-P results in the formation of UDP-GlcNAc, 
which is a precursor molecule for all other amino sugars necessary for multiple 
glycosylation reactions, resulting in the formation of glycoproteins, glycolipids, 
proteoglycans, and glycosaminoglycans
179
 (Figure 9). Thus increased HBP activation 
results in a rise in O-linked N-acetyl-D-glucosaminylation (O-GlcNAcylation).  
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Figure 9. The hexosamine biosynthetic pathway and protein O-GlcNAcylation. F6P branches off from 
glycolysis and is converted to GlucN-6-P by GFAT, using glutamine as an amino donor. GlucN-6-P is 
converted to UDP-GlcNAc which allows for the addition of GlcNAc groups to proteins via OGT. The 
reaction is reversible via O-GlcNAcase. OGT - O-GlcNAc transferase, O-GlcNAcase - O-GlcNAc 
hexosaminidase, PUGNAc - O-[2-acetamido-2-deoxy-D-glucopyranosylidene]-amino-N-phenylcarbamate, 
GlcNAc - N-acetylglucosamine. 
In eukaryotic cells a variety of nuclear and cytoplasmic proteins are modified at hydroxal 
groups of specific serine and threonine residues by O-linked N-acetylglucosamine (O-
GlcNAc) moieties
180,181
. The dynamic O-glycosidic linkage of GlcNAc to proteins is a 
reversible post-translational modification, differing from other glycosylation events as it 
takes place in the cytosol and nucleus
182
. The process of O-GlcNAcylation is catalyzed 
by O-GlcNAc transferase (OGT), with the reverse reaction under regulation of O-
GlcNAc hexosaminidase (O-GlcNAcase)
183
.  
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UDP-GlcNAc is the substrate for protein O-GlcNAcylation and can be synthesized in de 
novo fashion from glucose (via the HBP). Moreover, compounds such as glucosamine, 
streptozotocin, O-[2-acetamido-2-deoxy-D-glucopyranosylidene]-amino-N-
phenylcarbamate (PUGNAc), and 2-deoxyglucose augment the process of O-
GlcNAcylation by either increasing the availability of UDP-GlcNAc or via the inhibition 
of O-GlcNAcase
184–186
. The effects of O-GlcNAcylation on proteins are varied across cell 
types and in terms of its end result on protein function (Table 3). 
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Table 3: Protein O-GlcNAcylation  modulates various processes. 
Modifications caused by  
O-GlcNAcylation 
Outcomes 
Enzyme activity  Inhibition of eNOS187,188 
 Reduced activation of glycogen 
synthase in IR
189
 
Protein-protein interactions  Prevent untimely & ectopic 
interactions of Sp1
190
 
 Inhibits hydrophobic interactions 
between TAF110, holo-Sp1 and 
Sp1
191
 
 Inhibits Sp1 transcriptional 
capability
192
 
DNA-binding affinity  Regulation of PDX-1 DNA 
binding affinity & glucose-
stimulated insulin secretion in β-
cells
193
 
Subcellular localization  Translocation of proteins from 
cytosol to nucleus e.g. eIF-1
194
, La 
antigen
195
, neoglycoproteins
196
, 
glycoconjugates
197,198
 
Half life and proteolytic processing of 
proteins 
 Protect eIF-2 α-subunit from eIF-2 
kinase phosphorylation
199,200
 
 Protects Sp1 from cAMP-mediated 
degredation
201
 
 Regulate transactivation & 
turnover of estrogen receptor β202 
 
Studies by Du et al.
203
 on bovine aortic endothelial cells confirmed the involvement of 
hyperglycemia-induced increases in mitochondrial superoxide in terms of HBP activation. 
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This occurs via the inhibition of GAPDH activity, which diverts F6P from the glycolytic 
pathway and instead shuttles it into the formation of glucosamine. It can therefore be 
concluded that excessive HBP activation by hyperglycemia-induced mitochondrial 
superoxide overproduction may be responsible for derangements in both gene expression 
and protein function, leading to the development of diabetic complications. At the gene 
expression level, the exact mechanisms whereby increased HBP flux mediates 
hyperglycemia-induced gene expression are beginning to emerge. For example, Chen et 
al
204
 discovered that Sp1 sites regulate hyperglycemia-induced activation of the PAI-1 
promoter in vascular smooth muscle cells and covalent modification of Sp1 by GlcNAc 
may explain the link. Furthermore, glycosylated Sp1 is more transcriptionally active than 
its de-glycosylated form, indicating that HBP flux has a direct effect on protein function. 
To sum up, increased NOGP flux can elevate ROS levels with detrimental effects, e.g. 
cell death. Since we here propose that HIV-PIs can activate NOGPs, then this may 
provide a unique link between PIs and myocardial cell death.  
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The effect of PIs on cell death 
 
Programmed cell death is a vital cellular process by which the integrity and homeostasis 
of multicellular organisms is maintained. Apoptosis is controlled by a variety of cell 
signals, which may be extracellular (extrinsic inducers) or intracellular (intrinsic 
inducers). Extracellular signals include toxins
205
, hormones
206
, growth factors
207
, nitric 
oxide
208
 and cytokines
209
, which must either cross the cell membrane or transduce in 
order to be effective. These signals can either induce or repress apoptosis. Intracellular 
signaling is brought about by the cell as a response to stress, e.g. glucocorticosteroid 
binding to nuclear receptors
206
, heat
210
, radiation
211
, nutrient deprivation
212
, viral 
infection
213
, hypoxia
214
, and increased calcium concentrations
215
. 
 Apoptosis is initiated in the mitochondrion and endoplasmic reticulum (ER), with 
the release of cytochrome c (from mitochondria) and calcium (from the ER) into the 
cytosol - as messengers for this process. In support, Boehning et al.
216
 implicated calcium 
in the coordination of mitochondrial-ER interactions that drive apoptosis. Cytochrome c 
released from mitochondria in response to death signals binds to IP3 receptors in the ER 
membrane, promoting calcium dispatch. This causes an increase in cytosolic calcium 
concentrations resulting in calcium uptake by mitochondria.  The mass release of 
cytochrome c from mitochondria occurs at the same time. This allows for the formation 
and activation of an apoptosome (a protein complex that includes caspase and nuclease 
enzymes) that finalizes the apoptotic process (Figure 10).  
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Figure 10. Cytochrome c and calcium regulation of apoptosis. 1. Death stimuli induce permeability 
transition in the mitochondrial membrane; 2. Cytochrome c is released from the mitochondrion into the 
cytosol; 3. Cytochrome c translocates to the ER and binds to the IP3 receptor; 4. Calcium is released from 
the ER into the cytosol; 5. Calcium enters and stimulates adjacent mitochondria; 6. Mitochondria release 
cytochrome c; and 7. Cytosolic cytochrome c induces the formation of the apoptosome. 
Since calcium is involved in many other cellular processes its role in apoptosis is strictly 
regulated. For example, after activation of IP3 receptors the cytosolic anti-apoptotic 
transcription factor NF-κβ can be activated by a diffusible NF-κβ-activating factor that is 
released from the ER into the cytoplasm due to a decrease in intra-luminal calcium
217
. 
Deviations in this finely controlled process may manifest in various disease pathologies. 
For example, abnormal apoptosis can promote cancer development by allowing 
accumulation of dividing cells and by inhibiting removal of genetic variants with 
enhanced malignant potential
218
. HIV/AIDS may be regarded as an imbalance between 
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CD4 cell death and cell replacement. Apoptosis was induced in HIV-infected MT2 
lymphoblasts and activated normal peripheral blood mononuclear cells
219
. This may be 
mediated by the HIV-1 gp120 glycoprotein which binds to the CD4 antigen since 
incubation of normal CD4 cells with HIV-1 gp120 followed by crosslinking causes 
apoptosis when stimulated by antibodies against the T-cell receptor antigen
220
. 
 For the purpose of this study we investigated the effects of PIs on cell death by means of 
death markers caspase 3, Bcl-2 and Bax, and pBAD. In light of this, these modulators 
will now be briefly discussed. 
Caspase 3 
Caspases, pro-apoptotic cysteine proteases, are essential for programmed cell death. 
Fourteen different caspases have thus far been identified in humans, each involved in 
inflammation and cell death. For the purpose of this study, caspase 3 levels were 
investigated as a key marker for apoptosis. In support, studies by Kuida et al.
221
 and Woo 
et al.
222
 on caspase-3-knockout mice validated the necessity of caspase 3 for survival.  
Further studies also elucidated the effects of caspase 3 in a variety of cell types in 
humans
223,224
. Collectively these results are indicative of the involvement of caspase 3 in 
nuclear and morphological variations associated with the completion of apoptosis and the 
formation of apoptotic bodies.  
The mechanism of caspase 3 action in the mediation of such variations is the 
cleavage of essential structural components, along with the incapacitation of critical 
homeostatic and repair processes
225
. The majority of caspase substrates are cleaved 
specifically by caspase 3, as well as pro-caspases 2, 6, 7 and 9, further confirming the 
extensive involvement of caspase 3 and related proteases in cell death
225,226
.  
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HIV PI treatment can result in the inhibition of caspases
227,228
. This is to be 
expected as HIV PIs are responsible for the inhibition of the aspartyl protease of HIV and 
would thus also have a similar effect on other cellular proteases.  
Bcl-2 and Bax 
Previous studies involving the nematode Caenorhabditis elegans
229
 revealed that the 
worm protein CED-9 is the functional homologue of Bcl-2
230
 and that it is responsible for 
the regulation of the activation of CED-3
231
. Bcl-2 and its relatives are responsible for the 
regulation of the pathway that leads to the activation of caspases.  It is induced by a 
variety of cellular stressors. Mammalian Bcl-2 has at least 20 relatives, all of which share 
at least one conserved Bcl-2 homology domain, and can be either pro- (e.g. Bax and 
BH3-only) or anti-apoptotic (e.g. Bcl-xL, Bcl-w, A1 and Mc11). Members of the Bax 
family (promotes cell death) have sequences that overlap with the anti-apoptotic Bcl-2. 
Bcl-2 functions to inhibit apoptosis in response to certain cytotoxic events. This occurs 
by means of its hydrophobic carboxy-terminal domain, which aids in targeting Bcl-2 to 
the face of three intracellular membranes, i.e. the outer mitochondrial membrane, ER, and 
the nuclear envelope
232
.  
Bcl-2 is an essential membrane protein and Veis et al.
233
 found that it is crucial for every 
nucleated cell to have at least one Bcl-2 homolog present for its survival. This is the case 
since it is assumed that other anti-apoptotic proteins are not as effective in defending the 
cell against programmed cell death. Bax is widely distributed throughout the body and is 
thought to function mainly at the mitochondrion
234,235
. In healthy cells it is present as a 
cytosolic monomer but it undergoes conformational changes during apoptosis, where it 
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integrates into the mitochondrial membrane and oligomerizes, resulting in mitochondrial 
dysfunction, cytochrome c release, activation of caspases, and ultimately cell death
236
.  
pBAD 
BAD is a member of the BH3-only, pro-apoptotic family of Bcl-2. Its activity is regulated 
by extracellular survival signals and it is phosphorylated and inactivated (by growth 
factors) at three serine residues: Ser-112, Ser-136, Ser-155
237–239
. Phosphorylation of 
BAD is a reversible process so that in the absence of growth factors, it can bind to and 
deactivate Bcl-2, allowing for apoptosis to occur. When considering the context of HIV 
and HAART, studies done by Strack et al.
240
 confirmed the HIV-1 protease cleavage of 
Bcl-2, thereby increasing in apoptosis. However, no correlation could be found between 
PI treatment and an alteration in intracellular levels of anti-apoptotic markers such as 
Bcl-2
241
.
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Conclusion 
HIV/AIDS remains a global epidemic despite a decrease in new infections. While various 
forms of HAART are available, they each present with their own adverse effects. This 
review demonstrates the damaging cardio-metabolic effects of PI treatment, e.g. long-
term PI usage can result in the development of the MetS as well as a variety of CVD 
complications like atherosclerosis. Furthermore, PIs can increase ROS levels that could 
be detrimental to heart function. Finally, PIs can also induce hyperglycemia and IR that 
may be linked to even greater ROS production, with apoptosis as a putative end result. 
Thus while PIs significantly improve the life expectancy and quality of life of HIV-
infected individuals, its long term usage can result in damaging cardio-metabolic side-
effects. Moreover, mechanistic insights underlying such side-effects are not well 
understood especially in the heart.  It is therefore imperative that further research be done 
in this field to help improve future drug design and lighten the disease burden of those 
already infected with HIV/AIDS.  
We therefore hypothesize that PIs can alter the flux through the NOGPs leading to 
increased ROS production and apoptosis. The aim of this study was thus to assess the 
production of mitochondrial ROS following PI treatment, as well as to establish whether 
induction of NOGPs occurs and whether there is any correlation of the latter to increases 
in cell death. 
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Chapter 2 
The effects of protease inhibitor (Lopinavir/Ritonavir) treatment 
on in vitro reactive oxygen species levels, programmed cell 
death and NOGPs  
 
Stellenbosch University  http://scholar.sun.ac.za
 74 
Introduction 
As earlier discussed in Chapter 1 of this thesis, HIV/AIDS infection targets the immune 
system of affected individuals with downstream molecular effects such as excessively 
high ROS levels. Due to the sensitivity of mitochondrial DNA to increases in ROS, 
mitochondrial dysfunction may arise leading to the development of a plethora of adverse 
conditions, e.g. T2DM, cancer
1
 and CVD including atherosclerosis
2,3
. HAART and 
specifically PIs can also induce ROS and this is supported by a number of studies 
utilizing human-
4
, animal-
5–8
, and cell-based
9–13
 models. However, not much is known 
about the effects of PIs on the heart and we therefore propose higher myocardial ROS 
levels - in vitro.  
 
Increased ROS is also linked to a rise in cell death. For example, Pierce et al.
14
 found that 
increases in H2O2 induced apoptosis in blastocysts. Similarly Watson et al.
15
 found that in 
neutrophils higher Fas protein levels result in increased apoptosis, which can be inhibited 
by a rise in intracellular GSH. Ironically the mitochondrion is also involved in the 
induction of apoptosis via its release of cytochrome c in response to death signals
16
. Thus 
the mitochondrion is implicated in both the cause and effect of cell death. 
 
However, PI treatment may inhibit apoptosis. For example, since caspase 3 is a cysteine 
protease it would be inhibited by PIs resulting in a decrease in cell death
17,18
. No 
interrelation between PIs and the cellular levels of anti-apoptotic markers has been 
established
19
. Apoptosis plays a vital role in the maintenance of cell integrity and 
irregularities in the process may result in various disease pathologies e.g. cancer
20
 and the 
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proliferation of HIV/AIDS
21,22
.  
 
For the first part of this study, apoptotic markers investigated include: 1) Caspase 3, a 
pro-apoptotic marker responsible for the cleavage of key structural components in cells in 
addition to disenabling vital homeostatic and repair processes
23
, 2) Bcl-2, an anti-
apoptotic marker involved in the inhibition of cell death via interactions with the 
mitochondrial membrane, ER and nuclear envelope
24
, 3) Bax, which forms part of the 
Bcl-2 family but induces apoptosis via integration into the mitochondrial membrane
25
, 
and 4) pBad, the phosphorylated and thus deactivated form of BAD. BAD binds to and 
inhibits Bcl-2 thereby allowing apoptosis to occur
26–28
. We therefore propose an increase 
in PI-induced ROS generation and cell death in rat-derived cardiomyoblasts. 
 
The second part of this study attempted to gain greater insights into mechanisms of PI-
induced elevation of ROS levels. Since this remains unclear, we here proposed increased 
NOGP flux as a potential mechanism.  The four main pathways implicated in 
microvascular and macrovascular complications arising from PI-induced hyperglycemia 
and ROS production are the polyol pathway, AGE pathway, PKC pathway and HBP 
pathway. For the purpose of this study we investigated the role of PIs in the induction of 
the NOGPs in rat-derived cardiomyoblasts. 
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Materials and Methods 
Cell culture 
Rat-derived cardiomyoblasts (H9c2 cell line, ECACC No. 8809294) were cultured in T25 
flasks at 37°C in 5% CO2 in Dulbecco‟s Modified Eagle‟s Medium (DMEM) containing 
GlutaMAX™, 1 mM (low) glucose (Invitrogen, Carlsbad CA); and supplemented with 
10% FBS and 1% penicillin/streptomycin solution (Invitrogen, Carlsbad CA). Typically, 
cells with a passage number of 12-14 were used for experiments. Cells were cultured at a 
seeding density of approximately 300 000. A n=4 was used for all experiments.  
Evaluation of ROS production 
Cells were allowed to reach 70-80% confluency before being subjected to PI treatment, 
specifically Lopinavir/Ritonavir (Kaletra™, Abbot Laboratories, Abbot Park II), for a 
period of 24 hours. PIs were administered by resuspending crushed Lopinavir/Ritonavir 
tablets in DMSO. An initial stock solution of 20 mg/mL was made up, and diluted in 4 
mL DMEM per flask to achieve the final concentrations as indicated in Figure 1. Cells 
receiving no treatment were used as a control, whereas cells receiving only 48 μL 
(0.012% v/v) DMSO were employed to ascertain the effect of the vehicle. 
At the end of the treatment period, cells were harvested via trypsinization and the 
subsequent pellets were collected and treated with MitoSOX™ Red mitochondrial 
superoxide indicator dye (1:500; Invitrogen, Carlsbad CA) for 10 min at 37°C. 
MitoSOX™ Red mitochondrial superoxide indicator dye is a fluorogenic dye which is 
able to permeate live cells, specifically targeting mitochondria. Upon entering the 
mitochondria, MitoSOX™ Red reagent is rapidly oxidized by superoxide and exhibits 
red fluorescence as a result of the oxidation product binding to nucleic acids. The 
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oxidation of MitoSOX™ Red reagent is specific to superoxide and not to any other ROS- 
or RNS- (reactive nitrogen species) generating systems
29
.  
Cells were then centrifuged (5 000 × g, 3 min) and pellets washed and resuspended in 
with warm PBS. Hereafter the amount of mitochondrial ROS generated was assessed via 
flow cytometry (BD Bioscience FACSAria™, Becton Dickinson, San Jose CA), 
performed at the Central Analytical Facility (CAF) at Stellenbosch University.  
A dose response curve was set up to establish optimal dosage of PI required. Cell debris 
was gated out for analysis. Data were normalized to the control to eliminate the binding 
of MitoSOX™ to nuclear DNA following oxidation from affecting the results. Ultimately 
the Lopinavir/Ritonavir dosage of 240 μg/mL was selected. Previous studies on 
cardiomyocytes by Deng et al.
31
 used 9 432 μg/μL of Lopinavir/Ritonavir for 15 minutes. 
Here the concentration of PI is much higher, however, the treatment time is much less. 
Western blotting analysis 
Rat-derived cardiomyoblasts (H9c2) were cultured as mentioned previously. A PI 
concentration of 240 μg/mL was administered to the treatment group for a period of 24 
hours. Thereafter, cells were harvested and sonicated for 7 seconds in 1 mL 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 
1% Triton x-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA) and centrifuged 
twice at 7 500 × g for 10 minutes. The resultant supernatant was collected as the protein 
fraction. Protein concentration was determined by employing the Bradford technique, 
with BSA as the protein standard. 
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Samples for Western blotting were prepared by addition of a Laemmli sample buffer 
containing β-mercaptoethanol to a final protein concentration of 20 μg. Samples were 
boiled at 95°C for 5 minutes to ensure denaturation of proteins into a linear formation, 
capable of migrating through the SDS-PAGE gel. Briefly, prepared samples were then 
loaded in commercially available 10-well precast Mini-PROTEAN® TGX Stain-Free™ 
polyalcrylamide gels (Bio-Rad, Hercules CA) and subjected to electrophoresis in a 1× 
running buffer containing 25 mM Tris, 192 mM glycine, 0.1% SDS, and at pH 8.3 (Bio-
Rad, Hercules CA). 4μl of the protein marker peqGOLD (PEQLAB Ltd. Sarisbury 
Green) was loaded as an indicator of protein migration and protein size.  
Gels were electrophoresed at 250 V until adequate separation of proteins was 
achieved. Hereafter transfer of proteins from the gel to the membrane was performed by 
the employment of commercially available transfer packs in conjunction with the Trans-
Blot® Turbo™ Transfer system (Bio-Rad, Hercules CA). The system makes use of semi-
dry transfer, ensuring the migration of separated proteins from the gel to the pre-wet 
polyvinylidene fluoride (PVDF) membrane contained in the transfer pack, in 7 minutes.  
The membrane was then subjected to various washing steps in Tris-buffered saline 
solution containing Tween-20 (2 L TBS-T: 20 mM Tris-HCl, 500 mM NaCl, 2 mL 
Tween-20). Blocking for the primary antibody was performed for using 5% fat-free milk 
solution (5 g fat-free dry milk powder dissolved in 100 mL TBS-T solution). The 
membrane was incubated in primary antibody (1:1000) at 4°C, overnight (Table 1) 
Incubation in secondary antibody, (goat-anti-rabbit IgG-HRP, Santa Cruz 
Biotechnologies, CA), at 1:4000 concentration, was performed at room temperature for 1 
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hour. Visualization of the membrane was performed with enhanced chemiluminescence 
(ECL).  
Table 1: Antibody usage for Western blotting analysis 
 Primary antibody Supplier 
Cell Death 
Bcl2 α-rabbit Bcl2 Santa Cruz Biotechnologies, CA 
Caspase3 α-rabbit Caspase3 Cell Signaling Technology, MA 
pBad α-rabbit pBad Santa Cruz Biotechnologies, CA 
β-actin α-rabbit β-actin Santa Cruz Biotechnologies, CA 
Hexosamine biosynthetic pathway 
O-GlcNAc α-rabbit O-GlcNAc Cell Signaling Technology, MA 
 
Protein expression was determined by the adjusted percentage volume, (intensity 
units of pixels of band × mm
2
), after background subtraction (Quantity One Software 
v4.6.9, BioRad, Hercules CA), and normalized to β-actin to correct for loading variations. 
The adjusted volume for the control group was represented as 100%, and corresponding 
values for vehicle and treatment groups were expressed as a percentage of the average of 
the control. This method was performed for each experiment separately before all values 
were combined in the statistical program. A n=4 was used for each experimental group. 
Hexosamine biosynthetic pathway 
Western blotting analysis (as described above) was employed to determine total 
O-GlcNAc expression as a marker for HBP activation.  
Advanced glycation end product (AGE) pathway 
Methylglyoxal (MG) concentrations were measured by means of a commercial kit 
(OxiSelect™ MG ELISA Kit; Cell Biolabs, San Diego CA) to assess AGE pathway 
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activation. MG derivatives are formed via the Maillard reaction - products of this reaction 
are referred to as AGEs. MG levels were calculated from the standard curve (generated 
by plotting the absorbance values of standards against the protein concentration and 
employing the y=mx+c equation) and are expressed as nmol per μg protein.    
Protein kinase C (PKC) pathway 
The PKC assay was carried out using an ELISA-based commercially available kit (Enzo 
Life Sciences, Farmingdale NY) and protocol was followed as detailed in the kits 
instruction manual. PKC activity was determined from the standard curve (generated by 
plotting the absorbance values of standards against the protein concentration and 
employing the y=mx+c equation) and expressed per volume of lysate per minute. 
Polyol pathway 
D-sorbitol levels were measured as detailed in the instructions of a commercially 
obtained kit (BioVision K 631-100, Mountain View CA).  A standard curve was 
generated by plotting the absorbance values against concentration of protein standards 
and employing the y=mx+c equation. We then calculated the sorbitol concentration (C) 
of samples by using the sample amount (nmol) from the standard curve (Sa), sample 
volume (μL) used (Sv) and the dilution factor (D); C=Sa/Sv*D.    
Statistical analysis 
Statistical analysis was performed by one-way ANOVA and the Bonferroni post-hoc test 
was used to determine differences between groups (GraphPad Prism v5, San Diego CA). 
Data are presented as mean ± SEM, and values considered significant when p<0.05.   
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Results 
A significant increase in mitochondrial ROS was observed in cells treated with 240 
µg/mL PI (Figure 1). This dosage was thus employed in all subsequent cell culture 
experiments to assess the effects on NOGPs and cell death. 
Figure 1: Dose response curve to determine optimal PI dosage. Mitochondrial ROS production in 
arbitrary fluorescent units (AFU) was plotted against various dosages of Lopinavir/Ritonavir. *=p<0.05 vs. 
120 μg/mL, ##=p<0.01 vs. 60 μg/mL, $$$=p<0.001 vs. Control and Vehicle. 
Because of the significant PI-induced upregulation in mitochondrial ROS observed in rat-
derived cardiomyoblasts, we proposed a related increase in apoptosis. Here cells were 
subjected to PI treatment at the chosen dose and cell death markers were evaluated. 
However, no significant changes were observed for any of the apoptotic markers 
investigated (Figure 2). 
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Figure 2. Apoptosis in rat-derived cardiomyoblasts in response to 24 hour PI treatment. A) Caspase 3 
B) Bcl-2 C) The relationship between Bcl-2 and Bax D) pBad. Data presented as mean ± SEM. PI – 
protease inhibitor. 
Next we evaluated the effect of PIs on NOGPs in vitro. No significant differences were 
observed for all four pathways investigated (Figure 3). 
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Figure 3. NOGP analysis in rat-derived H9c2 cardiomyoblasts following PI treatment. A) AGE 
pathway, B) Polyol pathway, C) HBP, D) PKC pathway. Data presented as mean ± SEM. PI – protease 
inhibitor. 
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Discussion 
A significant increase in PI-induced mitochondrial ROS was observed in rat-derived 
cardiomyoblasts treated with 240 μg/ml Lopinavir/Ritonavir for 24 hours (Figure 1). This 
is in agreement with other studies showing increased ROS generation with PI treatment 
in cardiomyocytes
32
. Here the PI dosage is higher but the treatment time is shorter than in 
our study, yet notable increases in ROS are observed. Future studies could thus employ a 
similar model as the latter to ascertain whether NOGP induction occurs at an earlier time 
point. Nevertheless, we used this concentration of PI for all subsequent cell culture 
experiments when investigating apoptosis.  
No significant changes in apoptosis were observed in PI-treated rat-derived 
cardiomyoblasts (Figure 2). In agreement, Jiang et al.
33
 found that ARV treatment of 
human umbilical cord endothelial cells caused increases in ROS along with 
mitochondrial dysfunction but did not induce apoptosis, even after 48 hours. A proposed 
mechanism is due to the mitochondrion‟s dual function in ROS generation and apoptosis 
and that ROS-induced mitochondrial dysfunction may thus disrupt its role in cell death.  
Changes in NOGP flux were negligible for all four pathways investigated. Here we 
employed a PI dose and duration that significantly increased the amount of mitochondrial 
ROS produced. We are unclear how to explain these data but propose that a temporal 
study should be undertaken to gain additional insights in this regard. Here it would be 
useful to investigate whether NOGPs may be induced earlier or later in response to PI 
exposure. Therefore the possibility exists that our 24-hour time point may have „missed‟ 
any NOGP induction that could have occurred. Conversely, this induction may not have 
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occurred and we need to expose the cells to PIs for a longer time period, e.g. 48 hours. 
These are now ongoing studies in our laboratory.  Another possibility is that the NOGPs 
do not play a role in these experimental models, and that it is not a downstream target of 
ROS. The experiments suggested here may shed light on this possibility as well.   
Therefore it is evident that while PIs do induce significant increases in mitochondrial 
ROS in rat-derived cardiomyoblasts, the effects on apoptosis and NOGPs are 
inappreciable. In future, a wider variety of ROS sources should be also evaluated in order 
to ascertain the exact effects of PIs on ROS generation in vitro. For example, we only 
focused on mitochondrial-generated ROS and it would be useful to check extra-
mitochondrial ROS sources (e.g. NOX) and also RNS. It may also be worthwhile to 
investigate apoptosis in tissues as well in order to elucidate whether apoptosis would 
occur following a prolonged treatment period. 
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Conclusion 
In conclusion, our in vitro study demonstrates that notable increases in mitochondrial 
ROS occur following PI treatment but that this is unrelated to increases in cell death or 
NOGP induction. We therefore propose further investigation into alternative ROS 
sources as well as apoptotic markers in both cells and tissues generated from in vivo 
experimental models. 
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Chapter 3 
Analysis of the non-oxidative glucose pathways (NOGP) 
following protease inhibitor treatment (in vivo generated 
samples) 
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Introduction 
PIs form an integral part of HAART and are highly effective in suppressing viral load in 
HIV-infected patients. However, long-term therapy often leads to the development of 
numerous side-effects. For example, Lopinavir/Ritonavir usage causes diarrhea, nausea, 
and lipid abnormalities such as elevated cholesterol and triglycerides
1
. Furthermore, the 
metabolic alterations associated with PIs largely resemble the MetS, a combination of 
risk factors leading to future onset of T2DM and CVD
2
. Exacerbation of the MetS 
phenotype also leads to an increase in cardiovascular complications and IR
3
 amongst 
infected individuals, further increasing the disease burden.  
Various studies on cell-
4–6
, animal-
7–9
 and human-based
10–16
 models demonstrated 
increased plasma cholesterol and triglyceride levels, lipodystrophy and IR as the most 
common metabolic perturbations with PI usage. Collectively, these serious adverse 
effects lead to the development of inflammation, stressing the myocardium and 
eventually progressing to IR and cardiac dysfunction
14,17
. 
Since PIs induce alterations in glucose metabolism, the aim of this study was to 
determine whether these changes affect regulation of the NOGPs. As before, we again 
propose increases in NOGP flux as a potential mechanism for PI-induced elevated ROS 
levels. The same four pathways investigated previously in vitro (Chapter 2) will be 
assessed, i.e. the polyol pathway, HBP, AGE pathway and PKC pathway. Here heart and 
liver tissues from two separate rat models utilizing PI therapy were utilized to investigate 
our hypothesis. 
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Materials and Methods 
Protein extraction 
We employed tissues collected from two models of PI treatment of rats, i.e. by a) osmotic 
mini-pump utilization (developed by Dr. Kathleen Reyskens
18
), and b) jelly 
administration (completed by Mr. Burger Symington in our department).  For the osmotic 
mini-pump method, male Wistar rats were subjected to physiologically relevant dose of 
Lopinavir/Ritonavir (i.e. 7.1 ± 2.9 μg/mL) via a mini-osmotic pump for a period of 8 
weeks, whereas for the jelly-based method, 44 mg/kg body weight dose of 
Lopinavir/Ritonavir was dissolved in jelly and administered orally for a period of 16 
weeks. This latter dosage was determined after body surface area (BSA) conversion, 
according to Reagan-Shaw et al
19
. At the end of the respective treatment periods, rats 
were sacrificed and cardiac and hepatic tissues were harvested from both animal models. 
Experimental groups for Group A are as follows: control rats underwent mock surgery, 
vehicle rats received a mini-osmotic pump containing only ethanol whereas treatment rats 
received a PI-containing pump for a total of 8 weeks (n=8 per group). For Group B, control 
rats received no intervention, vehicle rats received only jelly whereas treatment rats 
received jelly infused with PIs (n=6 per group).  The use of animals and procedures were 
reviewed and approved by the Animal Research Ethics Committee of the Faculty of Natural 
Sciences of Stellenbosch University (Group A: application numbers 2006B02006, 
11NF_REY01, SU_ACUM11_00006, and related amendments, and Group B: application 
numbers SU_ACUM11_00007A and related amendments). This study adheres to the guidelines 
set out by the National Institutes of Health‟s Guide for the Care and Use of Laboratory 
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Animals and performed with the approval of the Animal Ethics Committee of Stellenbosch 
University (South Africa).  
Collected rat tissues (heart and liver) were homogenized in RIPA buffer (50 mM Tris-
HCl pH 7.4, 150 mM NaCl, 1% Triton x-100, 1% Sodium deoxycholate, 0.1% SDS, 1 
mM EDTA) and centrifuged twice at 7500 × g for 10 minutes. The resultant supernatant 
was collected as the cytosolic protein fraction. Protein concentration was determined by 
employing the Bradford technique, with BSA as the protein standard. 
Hexosamine biosynthetic pathway 
Western blotting analysis (as previously described in Chapter 2) was employed to 
determine total O-GlcNAc expression as a marker for HBP activation.  
Advanced glycation end product (AGE) pathway 
Methylglyoxal (MG) concentrations were measured by means of a commercial kit 
(OxiSelect™ MG ELISA Kit; Cell Biolabs, San Diego CA) to assess AGE pathway 
activation (as previously described in Chapter 2). 
Protein kinase C (PKC) pathway 
The PKC assay was carried out using an ELISA-based commercially available kit (Enzo 
Life Sciences, Farmingdale NY) and protocol was followed as detailed in the kits 
instruction manual (as previously described in Chapter 2). 
Polyol pathway 
D-sorbitol levels were measured as detailed in the instructions of a commercially 
obtained kit (BioVision K 631-100, Mountain View CA), as previously described in 
Chapter 2. 
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Statistical analysis 
Statistical analysis was performed by one-way ANOVA and the Bonferroni post-hoc test 
was used to determine differences between groups (GraphPad Prism v5, San Diego CA). 
Data are presented as mean ± SEM, and values considered significant when p<0.05. 
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Results 
The results from both rat models are presented grouped per tissue type (heart, liver), per 
pathway investigated. Hereafter the 8-week group (mini-osmotic pump administration) 
will be referred to as Group A and the 16-week group (jelly-based administration) as 
Group B. Group A consisted of n=8 rats per experimental group whereas Group had n=6 
rats per experimental group.  
For the AGE pathway we observed a significant decrease in MG in the liver of Group A 
rats but not in Group B rats (Figure 1). Here PI treatment decreased MG levels to 13.63 ± 
2.624 ng/μg protein vs. control 31.88 ± 6.607 ng/μg protein (p<0.01); and vs. vehicle 
34.22 ± 3.723 ng/μg protein (p<0.01). 
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Figure 1. AGE pathway analysis in the rat heart and liver following PI treatment. Results are 
presented as the amount of MG produced per μg protein in the sample. Group A results are presented on the 
left and Group B on the right, for liver and heart respectively. Data presented as mean ± SEM. *p<0.01 vs. 
Control, #p<0.01 vs. Vehicle. PI – protease inhibitor. 
Next sorbitol levels were assessed as marker of polyol pathway induction. No significant 
differences were observed between groups. 
 
Stellenbosch University  http://scholar.sun.ac.za
 97 
 
Figure 2. Polyol pathway analysis in the rat heart and liver following PI treatment. Results are 
presented as the amount of sorbitol produced per μL protein in the sample. Group A results are presented 
on the left and Group B on the right, for liver and heart respectively. Data presented as mean ± SEM. PI – 
protease inhibitor. 
 
The HBP pathway was next investigated but no significant differences were observed 
between groups. 
Stellenbosch University  http://scholar.sun.ac.za
 98 
 
 
Figure 3. HBP pathway analysis in the rat heart and liver following PI treatment. Results are 
presented as the amount of O-GlcNAc normalized to β-actin. Group A results are presented on the left and 
Group B on the right, for liver and heart respectively. Data presented as mean ± SEM. PI – protease 
inhibitor. 
Finally, the PKC pathway was investigated. Once again no significant differences were 
observed between groups. 
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Figure 4. PKC pathway analysis in the rat heart and liver following PI treatment. Results are 
presented as the amount of PKC kinase activity observed. Group A results are presented on the left and 
Group B on the right, for liver and heart respectively. Data presented as mean ± SEM. PI – protease 
inhibitor. 
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Discussion 
Significant down-regulation of the AGE pathway was observed in the liver of Group A. 
To further elucidate the cause of this observation, separate experiments were performed 
(by Dr. Kathleen Reyskens
18
) to assess the total, free and oxidized GSH levels. Here the 
rationale was based on studies by Lander et al.
20
 on rat pulmonary artery smooth muscle 
cells that showed depletion of intracellular GSH resulted in increased sensitivity of cells 
to AGE-mediated pathway induction. We therefore expected that the converse would be 
valid: an increase in intracellular GSH would allow for a decrease in AGE-mediated 
pathway induction. However, results for this study remain inconclusive as no significant 
changes were observed in GSH levels in tissues (data not shown). 
For the rest of the pathways investigated, no significant differences were observed 
between experimental groups. For Group A we attribute this to the duration of exposure 
to PIs, i.e. eight weeks might not be long enough for PIs to induce changes in the NOGPs. 
Most human-based studies highlighting the adverse effects of PIs employ a treatment 
period of more than six months
21–24
. However, the longer treatment period for Group B 
also did not result in any significant changes. Although changes to the NOGP flux are not 
significant, the data suggest that the level of pathway induction for Group B is higher 
than Group A in some instances. For example, the amount of MG produced in the heart 
and liver of Group B rats is higher than Group A (Figure 1). A similar trend exists for the 
rest of the pathways investigated (Figure 2-4). However, the jelly-based model resulted in 
a less severe phenotype than the mini-osmotic pump method. For example, the mini-
osmotic pump method elicited several metabolic changes after 8 weeks
25
 while the jelly-
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based method did not (Symington, unpublished data). This may be the case since the 
mini-osmotic pump delivers PIs at a steady rate and in a continuous fashion, while the 
jelly-based method only delivers the PIs as specific times (when ingested).  This may 
help explain why 8 weeks by the mini-osmotic pump results in a more severe phenotype. 
Therefore increasing the duration of exposure to PI treatment – especially with the mini-
osmotic pump model - may result in more conclusive evidence for NOGP induction in 
future.  However, further studies are required to test whether this is indeed the case. 
Another concern for the jelly-based method (Group B) is that it contains ingredients that 
can adversely affect experimental results.  For example, according to Coleman and 
Anderson
26
, the original formulation for jelly-type confections contains sorbitol as an 
alternative sweetener. In agreement, our results for polyol pathway induction in Group B 
show higher sorbitol levels when compared to the control (Figure 2), especially in the 
liver. Thus the vehicle utilized may negatively affect results for Group B and future 
studies should consider an alternative vehicle for drug administration. 
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Conclusion 
In conclusion, our study demonstrates that PI exposure does not activate NOGPs, 
suggesting that these pathways are not detrimental in terms of cardio-metabolic 
dysfunction found with PIs. However, the liver exhibited lower AGE pathway activation 
that needs more studies to clarify its significance in terms of metabolic dysfunction found 
in this model (mini-osmotic pump). We propose future studies with modifications to the 
current rat models in order to evaluate the effects of PIs on the NOGPs. 
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